¹ú²ú³Ô¹Ï¸£Àû

Memorial Sloan Kettering Cancer Center, The Rockefeller University and ¹ú²ú³Ô¹Ï¸£Àû announced on Oct. 31 that they have established a new drug discovery company called Bridge Medicines.

Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

"Bridge Medicines is a transformative concept for therapeutics development that will provide enormous hope to patients and incredibly exciting opportunities for researchers to take their discoveries into the clinic," said ¹ú²ú³Ô¹Ï¸£Àû Interim Dean Augustine M.K. Choi. "¹ú²ú³Ô¹Ï¸£Àû is honored to be part of this groundbreaking investment in medicine."

.